Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease

被引:10
|
作者
Sharma, Rajani [1 ,2 ,11 ]
Simon, Tracey G. [3 ]
Hagstrom, Hannes [4 ,5 ,6 ]
Lochhead, Paul [7 ]
Roelstraete, Bjorn [8 ]
Soderling, Jonas [3 ]
Verna, Elizabeth C. [1 ,2 ]
Emond, Jean [1 ]
Ludvigsson, Jonas F. [2 ,8 ,9 ,10 ]
机构
[1] Columbia Univ, Ctr Liver Dis & Transplantat, Div Digest & Liver Dis, Irving Med Ctr, New York, NY USA
[2] Columbia Univ, Dept Med, Div Digest & Liver Dis, Coll Phys & Surg, New York, NY USA
[3] Massachusetts Gen Hosp, Liver Ctr, Div Gastroenterol, Boston, MA USA
[4] Karolinska Univ Hosp, Ctr Digest Dis, Unit Hepatol, Stockholm, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
[6] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[7] GlaxoSmithKline PLC, London, England
[8] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[9] Orebro Univ Hosp, Dept Pediat, Orebro, Sweden
[10] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England
[11] Columbia Univ, Ctr Liver Dis & Transplantat, Irving Med Ctr, 622 West 168th St,PH14,Suite 202, New York, NY 10032 USA
基金
瑞典研究理事会; 美国国家卫生研究院;
关键词
Cirrhosis; Hepatocellular Carcinoma; Fibrosis; CIRRHOSIS; DECOMPENSATION; REGISTER; COHORT;
D O I
10.1016/j.cgh.2023.04.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Little is known about the potential impact of statins on the progression of noncirrhotic chronic liver diseases (CLDs) to severe liver disease. METHODS: Using liver histopathology data in a nationwide Swedish cohort, we identi fi ed 3862 noncirrhotic individuals with CLD and statin exposure, de fi ned as a statin prescription fi lled for 30 or more cumulative de fi ned daily doses. Statin users were matched to 3862 (statin) nonusers with CLD through direct 1:1 matching followed by propensity score matching. Cox regression was used to estimate hazard ratios (HRs) for the primary outcome of incident severe liver disease (a composite of cirrhosis, hepatocellular carcinoma, and liver transplantation/liverrelated mortality). RESULTS: A total of 45.3% of CLD patients had nonalcoholic fatty liver disease, 21.9% had alcohol -related liver disease, 17.7% had viral hepatitis, and 15.1% had autoimmune hepatitis. During follow-up evaluation, 234 (6.1%) statin users vs 276 (7.1%) nonusers developed severe liver disease. Statin use was associated with a decreased risk of developing severe liver disease (HR, 0.60; 95% CI, 0.48 - 0.74). Statistically signi fi cantly lower rates of severe liver disease were seen in alcohol -related liver disease (HR, 0.30; 95% CI, 0.19 - 0.49) and in nonalcoholic fatty liver disease (HR, 0.68; 95% CI, 0.45 - 1.00), but not in viral hepatitis (HR, 0.76; 95% CI, 0.51 - 1.14) or autoimmune hepatitis (HR, 0.88; 95% CI, 0.48 - 1.58). Statin use had a protective association in both pre fi brosis and fi brosis stages at diagnosis. Statin use was associated with lower rates of progression to cirrhosis (HR, 0.62; 95% CI, 0.49 - 0.78), hepatocellular carcinoma (HR, 0.44; 95% CI, 0.27 - 0.71), and liver -related mortality (HR, 0.55; 95% CI, 0.36 - 0.82). CONCLUSIONS: Among individuals with noncirrhotic CLD, incident statin use was linked to lower rates of severe liver disease, suggesting a potential disease -modifying role.
引用
收藏
页码:749 / 759.e19
页数:30
相关论文
共 50 条
  • [1] Statins for treatment of chronic liver disease
    Marrache, Mohamad Kareem
    Rockey, Don C.
    CURRENT OPINION IN GASTROENTEROLOGY, 2021, 37 (03) : 200 - 207
  • [2] Liver stiffness predicts incident severe liver disease in patients with chronic liver disease
    Hegmar, Hannes
    Wester, Axel
    Aleman, Soo
    Backman, Jens
    Degerman, Erik
    Ekvall, Hakan
    Lund, Katarina
    Lundgren, Asa
    Nasr, Patrik
    Shahnavaz, Afshin
    Vessby, Johan
    Westin, Johan
    Onnerhag, Kristina
    Hagstrom, Hannes
    JOURNAL OF HEPATOLOGY, 2022, 77 : S30 - S30
  • [3] Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression?
    Price, Jennifer C.
    Tien, Phyllis C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (10): : 1506 - 1507
  • [4] Advanced liver fibrosis is associated with decreased gait speed in older patients with chronic liver disease
    Fudeyasu, Kenichi
    Ushio, Kai
    Nomura, Takuo
    Kawae, Toshihiro
    Iwaki, Daisuke
    Nakashima, Yuki
    Nagao, Akiko
    Hiramatsu, Akira
    Murakami, Eisuke
    Oka, Shiro
    Mikami, Yukio
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] ASSOCIATION BETWEEN STATINS AND CHRONIC LIVER DISEASE PROGRESSION
    Smith, Nicholas
    Schreiner, Andrew
    Koch, David
    HEPATOLOGY, 2024, 80 : S1554 - S1554
  • [6] Statins for hyperlipidemia in patients with chronic liver disease: Are they safe?
    Vuppalanchi, Raj
    Chalasani, Naga
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (07) : 838 - 839
  • [7] How to use statins in patients with chronic liver disease
    Russo, MW
    Jacobson, IM
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2004, 71 (01) : 58 - 62
  • [8] The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis
    Carlos Moctezuma-Velázquez
    Juan G. Abraldes
    Aldo J. Montano-Loza
    Current Treatment Options in Gastroenterology, 2018, 16 (2) : 226 - 240
  • [9] Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
    Hashimoto, Yoshitaka
    Hamaguchi, Masahide
    Okamura, Takuro
    Nakanishi, Naoko
    Obora, Akihiro
    Kojima, Takao
    Fukui, Michiaki
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (02) : 308 - 316
  • [10] The gut-liver axis in chronic liver disease associated with severe COVID-19
    Chen, Jiezhong
    Vitetta, Luis
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E1103 - E1103